Exploring the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry.
Journal
Journal of chemical information and modeling
ISSN: 1549-960X
Titre abrégé: J Chem Inf Model
Pays: United States
ID NLM: 101230060
Informations de publication
Date de publication:
12 06 2023
12 06 2023
Historique:
medline:
13
6
2023
pubmed:
12
5
2023
entrez:
12
5
2023
Statut:
ppublish
Résumé
De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time- and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development. In this paper, we explore the combination of two rapidly developing fields with lead candidate discovery in the drug development process. First, artificial intelligence has already been demonstrated to successfully accelerate conventional drug design approaches. Second, quantum computing has demonstrated promising potential in different applications, such as quantum chemistry, combinatorial optimizations, and machine learning. This article explores hybrid quantum-classical generative adversarial networks (GAN) for small molecule discovery. We substituted each element of GAN with a variational quantum circuit (VQC) and demonstrated the quantum advantages in the small drug discovery. Utilizing a VQC in the noise generator of a GAN to generate small molecules achieves better physicochemical properties and performance in the goal-directed benchmark than the classical counterpart. Moreover, we demonstrate the potential of a VQC with only tens of learnable parameters in the generator of GAN to generate small molecules. We also demonstrate the quantum advantage of a VQC in the discriminator of GAN. In this hybrid model, the number of learnable parameters is significantly less than the classical ones, and it can still generate valid molecules. The hybrid model with only tens of training parameters in the quantum discriminator outperforms the MLP-based one in terms of both generated molecule properties and the achieved KL divergence. However, the hybrid quantum-classical GANs still face challenges in generating unique and valid molecules compared to their classical counterparts.
Identifiants
pubmed: 37171372
doi: 10.1021/acs.jcim.3c00562
pmc: PMC10268960
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3307-3318Références
IEEE Trans Pattern Anal Mach Intell. 2021 Dec;43(12):4217-4228
pubmed: 32012000
Science. 2020 Aug 28;369(6507):1084-1089
pubmed: 32855334
Science. 2005 Sep 9;309(5741):1704-7
pubmed: 16151006
Oncotarget. 2017 Nov 9;9(5):5665-5690
pubmed: 29464026
Expert Opin Drug Discov. 2019 Aug;14(8):791-803
pubmed: 31179763
J Phys Chem A. 2021 Mar 11;125(9):1827-1836
pubmed: 33635672
J Cheminform. 2009 Jun 10;1(1):8
pubmed: 20298526
Nat Chem. 2012 Jan 24;4(2):90-8
pubmed: 22270643
Sci Data. 2014 Aug 05;1:140022
pubmed: 25977779
Sci Rep. 2019 Dec 11;9(1):18911
pubmed: 31827124
Nat Biotechnol. 2019 Sep;37(9):1038-1040
pubmed: 31477924
J Chem Inf Model. 2012 Nov 26;52(11):2864-75
pubmed: 23088335
Trends Pharmacol Sci. 2019 Aug;40(8):592-604
pubmed: 31320117
J Chem Inf Model. 2023 Feb 13;63(3):695-701
pubmed: 36728505
J Chem Inf Model. 2019 Mar 25;59(3):1096-1108
pubmed: 30887799
Nat Chem. 2010 Feb;2(2):106-11
pubmed: 21124400
Nat Rev Drug Discov. 2005 Aug;4(8):649-63
pubmed: 16056391
Int J Mol Sci. 2021 Feb 07;22(4):
pubmed: 33562347
Drug Discov Today. 2021 Jan;26(1):80-93
pubmed: 33099022
J Cheminform. 2019 Dec 3;11(1):74
pubmed: 33430938
JAMA. 2020 Mar 03;323(9):844-853
pubmed: 32125404
ACS Med Chem Lett. 2020 Jul 14;11(8):1496-1505
pubmed: 32832015
AAPS J. 2022 Jan 4;24(1):19
pubmed: 34984579
Mol Pharm. 2018 Oct 1;15(10):4311-4313
pubmed: 30269508
Chem Rev. 2019 Oct 9;119(19):10856-10915
pubmed: 31469277
Future Med Chem. 2018 Sep 1;10(17):2021-2024
pubmed: 30058835
Nat Commun. 2014 Jul 23;5:4213
pubmed: 25055053
Phys Rev Lett. 2022 Mar 18;128(11):110501
pubmed: 35363009
Oncotarget. 2017 Feb 14;8(7):10883-10890
pubmed: 28029644
Comput Struct Biotechnol J. 2021 Aug 12;19:4538-4558
pubmed: 34471498
Comput Biol Med. 2022 Jun;145:105403
pubmed: 35339849
Mol Pharm. 2016 Jul 5;13(7):2524-30
pubmed: 27200455
Nature. 2017 Sep 13;549(7671):242-246
pubmed: 28905916
Phys Rev Lett. 2018 Jul 27;121(4):040502
pubmed: 30095952
Mol Pharm. 2017 Sep 5;14(9):3098-3104
pubmed: 28703000
J Chem Inf Model. 2020 Dec 28;60(12):5682-5698
pubmed: 32686938
Front Pharmacol. 2020 Dec 18;11:565644
pubmed: 33390943